{"id":49,"date":"2025-08-11T12:18:56","date_gmt":"2025-08-11T12:18:56","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=49"},"modified":"2025-08-11T16:02:42","modified_gmt":"2025-08-11T16:02:42","slug":"china-bd-deal-fosun-and-expedition-achieved-a-525-million-license-on-dpp-1-i-xh-s004","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/49.html","title":{"rendered":"[China BD Deal] Fosun and Expedition achieved a 645 million license on DPP-1 i XH-S004"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<p>Announced Date: 2025-08-11 (August 11, 2025)<\/p>\n\n\n\n<p>Asset Name: XH-S004<\/p>\n\n\n\n<p>Licensor: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (\u201cFosun Pharma\u201d; stock code: 600196.SH, 02196.HK) (Headquarter\uff0cShanghai,  China)<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Licensee (Buyer): Licensee (Buyer): Expedition Therapeutics Inc. (Expedition, USA)<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Asset Target: Oral DPP-1 inhibitor<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Current Stage: China phase II\u3001phase Ib<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Forsun has granted Expedition an exclusive license to develop, manufacture, and commercialize XH-S004 outside Great China<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of&nbsp;$17 million<\/p>\n\n\n\n<p>Milestone payments up to &nbsp;$102 million <\/p>\n\n\n\n<p> (if certain development, regulatory milestones are achieved)<\/p>\n\n\n\n<p>Milestone payments up to \u00a0$525 million(if certain commercial milestones are achieved)<\/p>\n\n\n\n<p>Other fee<\/p>\n\n\n\n<p>Total up to 645 million<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Link:<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-08-11 (August 11, 2025) Asset Name: XH-S004 Licensor: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. &hellip; <a title=\"[China BD Deal] Fosun and Expedition achieved a 645 million license on DPP-1 i XH-S004\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/49.html\"><span class=\"screen-reader-text\">[China BD Deal] Fosun and Expedition achieved a 645 million license on DPP-1 i XH-S004<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-49","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/49","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=49"}],"version-history":[{"count":3,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/49\/revisions"}],"predecessor-version":[{"id":53,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/49\/revisions\/53"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=49"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=49"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=49"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}